Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Provectus Reports Encouraging Clinical Data At ASCO On Treatment Of Metastatic Melanoma With PV-10
Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and caused selective tumor destruction in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)," in the General Poster Session.

Hormone Levels Contribute To Stress Resilience
It is important to understand what biological mechanisms contribute to an individual"s capacity to be resilient under conditions of extreme stress, such as those regularly experienced by soldiers, police, and firefighters. Dr. Charles A. Morgan III and his colleagues from Yale University and the VA National Center for PTSD have worked closely with collaborators at the Special Forces Underwater Warfare Operations Center to study special operations soldiers enrolled in the military Combat Diver Qualification Course (CDQC).
News of the day
Experts: Big Tobacco Dead By 2047, Possibly Sooner
President Barack Obama"s signature on a bill this week to grant the Food and Drug Administration (FDA) regulatory authority over tobacco was historic, and represents a step in the march to eliminate tobacco use in this country by 2047, two national tobacco experts said recently (June 25).
Cardiovascular

U.S. Food And Drug Administration Approves ONGLYZA™ (saxagliptin) For The Treatment Of Type 2 Diabetes Mellitus In Adults

and effectiveness of ONGLYZA™ (saxagliptin) in pediatric patients have not been established. Bristol-Myers Squibb and AstraZeneca Collaboration Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life. About AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of prescription medicines and supplier for healthcare services. AstraZeneca is one of the world"s leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. ONGLYZA is a trademark of the Bristol-Myers Squibb Company. AstraZeneca

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009